Navigation Links
Twins Pitcher Glen Perkins Kicks Off 7th Anniversary of Fitness Program in MPS
Date:1/16/2009

MINNEAPOLIS, Jan. 16 /PRNewswire-USNewswire/ -- More than 15,000 students at 53 Minneapolis Public Schools (MPS) sites will participate in the Presidential Active Lifestyle Award (PALA) program sponsored by the General Mills Foundation, AchieveMpls and MPS.

Richard Green Central Park Community School students will host guest speaker and Minnesota Twins starting pitcher Glen Perkins, along with Minneapolis Mayor R.T. Rybak, General Mills Foundation Executive Director Ellen Luger and AchieveMpls Chief Executive Officer Catherine Jordan. During the kickoff, students will lead attendees in a physical activity.

PALA was created to recognize those children and youth who begin and continue regular physical activity as a part of their daily lives in school and at home. The six-week program encourages second- through eighth-grade students to set the goal of participating in physical activity for one hour each day, five days a week.

To receive the PALA award, students from grades 2-8 must do any kind of physical activity that results in increased heart rate and breathing, for 60 minutes a day, five days a week during the duration of the six-week program. Participating students who meet their physical activity goals will be awarded an engraved medal, as well as a presidential badge and certificate. Last year, over 6,500 MPS students earned the award.

WHAT: General Mills Presidential Active Lifestyle Award program kick-off assembly

WHEN: Friday, January 16, from 10:00 - 10:30 a.m.

WHERE:

Green Central Park Community School

3416 Fourth Ave. S.

Minneapolis, MN 55408


'/>"/>
SOURCE AchieveMpls
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Overweight Twins Battle the Bulge and Gain A New Lease on Life in National Body Challenge: Twins Edition on Discovery Health
2. Twins study shows genetic basis for face and place recognition
3. Congenital heart defects increasing among IVF twins
4. Formerly Conjoined Twins Leave Packard Childrens Hospital; Heading Home to Costa Rica
5. Baby Madness is Sweeping the Nation! Forty Sets of Twins and Triplets Hit the Court in Discovery Healths BABY MADNESS: MULTIPLES
6. Parents of twins report more mental health symptoms than parents of singletons
7. Uterus Size May Predict Risk for Premature Twins After IVF
8. Vaginal/Caesarean combo delivery of twins safe, UT Southwestern-led research finds
9. Phillies Pitcher Jamie Moyer and Wife Karen Continue National Expansion - Bringing Bereavement Camps for Kids to Every Major League Baseball City
10. Height of Pitchers Mound Can Strain Shoulders
11. PUR Water Filtration Systems Can Remove Pharmaceuticals Identified in U.S. Tap Water - More Than 99 Percent for PUR Faucet Filters and More Than 96 Percent for PUR Pitchers*
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 2For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 3TaiGen Biotechnology Reports Phase I and Preclinical Data for TG-0054 at the 2009 American Society of Hematology (ASH) Annual Meeting 2New FDA Approved Breast Cancer Screening Tool 2New FDA Approved Breast Cancer Screening Tool 3KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 1KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 2KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 3KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 4KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 5KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 6Merrimack Pharmaceuticals Names Clet Niyikiza Ph D Senior Vice President Development 14175 1Merrimack Pharmaceuticals Names Clet Niyikiza Ph D Senior Vice President Development 14175 2Alzheimers Soars Global Focus Needed 3A Study 57748 1Alzheimers Soars Global Focus Needed 3A Study 57748 2Alzheimers Soars Global Focus Needed 3A Study 57748 3
Other Medicine Technology:Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 2Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 3Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 4Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 5Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 6Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 2Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 3Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 4Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 5Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 6Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 7Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 8Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 9Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 10